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A B S T R A C T
Background: Psychotic disorders are characterized by prominent deficits in associative learning and memory for which there are currently no effective treatments.
Functional magnetic resonance imaging (fMRI) studies in psychotic disorders have identified deficits in fronto-temporal activation during associative learning and
memory. The underlying pathology of these findings remains unclear. Postmortem data have suggested these deficits may be related to loss of muscarinic M1 receptor
mediated signaling. This is supported by an in-vivo study showing improvements in these symptoms after treatment with the experimental M1/4 receptor agonist
xanomeline. The current study tests whether reported deficits in fronto-temporal activation could be mediated by loss of M1 receptor signaling in psychotic disorders.
Methods: Twenty-six medication-free subjects diagnosed with a psychotic disorder and 29 age-, gender-, and IQ-matched healthy controls underwent two functional
magnetic resonance imaging (fMRI) sessions, one under placebo and one under selective M1 antagonist biperiden, while performing the paired associated learning
task. M1 binding potentials (BPND) were measured in the dorsolateral prefrontal cortex (DLPFC) and hippocampus using 123I-IDEX single photon emission computed
tomography.
Results: In the subjects with psychotic disorders DLPFC hypoactivation was only found in the memory phase of the task. In both learning and memory phases of the
task, M1 antagonism by biperiden elicited significantly greater hyperactivation of the parahippocampal gyrus and superior temporal gyrus in subjects with a
psychotic disorders compared to controls. Greater hyperactivation of these areas after biperiden was associated with greater hippocampal M1 receptor binding during
learning, with no association found with M1 receptor binding in the DLPFC. M1 receptor binding in the DLPFC was related to greater functional sensitivity to
biperiden of the cingulate gyrus during the memory phase.
Conclusion: The current study is the first to show differences in M1 receptor mediated functional sensitivity between subjects with a psychotic disorder and controls
during a paired associate learning and memory task. Results point to subjects with psychotic disorders having a loss of M1 receptor reserve in temporal-limbic areas.
1. Introduction
Psychotic disorders affect approximately 3% of the general popu-
lation (Perälä et al., 2007). Aside from the positive and negative
symptoms, psychotic disorders are characterized by cognitive impair-
ments that develop in approximately 80 to 85% of patients. These
symptoms often develop before the onset of the other symptoms and
have been found to be the strongest predictor of illness progression and
relapse (Green et al., 2004). Cognitive symptoms do not respond to
currently available antipsychotic treatments and persist even after
other symptoms have been treated. Although several domains of cog-
nition are affected, executive functioning and learning and memory
processes have been shown to be most impaired (Barch and Ceaser,
2012; Murray et al., 2010; Sheffield et al., 2018). Specifically patients
with psychotic disorders have deficits in associative learning and
memory. Through associative learning and memory relationships be-
tween unrelated items are encoded and retrieved and relies on both
executive functioning and learning and memory processes. Severity of
these deficits have been shown to be an important predictor of poor
functional outcome, and exist independent of poor concentration, ad-
ministered medication, and presence of positive symptoms (Barch and
Sheffield, 2014; Barnett et al., 2005).
Using functional magnetic resonance imaging (fMRI), studies have
investigated alterations in underlying brain activation during associa-
tive learning and memory in psychotic disorders. Significant hypo-ac-
tivation of the dorsolateral prefrontal cortex (DLPFC) and increased
activation of the parahippocampal gyrus are most consistently reported
(Ragland et al., 2012, 2009, 2004). It has been suggested that findings
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of the increased parahippocampal gyrus activation may be a compen-
satory mechanism. Meta-analytical studies, however, highlight a high
level of inconsistencies in reported results (Kraguljac et al., 2013).
These inconsistencies have mainly been attributed to the high hetero-
geneity among patient cohorts studied, with patients in different phases
of the disorder (first episode to chronic) and under different anti-
psychotic treatment regiments (Kraguljac et al., 2013).
Impairments in associative learning and memory processes have
shown little to no improvement under antipsychotic treatment and re-
cently it has been proposed that lowered signaling of the muscarinic
system, a system not targeted by most antipsychotic treatments, could
underlie these abnormalities (Carruthers et al., 2015; Erskine et al.,
2019). This neurotransmitter system became implicated after studies
showed reversible deficits in associative learning and memory after
administration of anti-muscarinic agents in healthy subjects and sub-
jects with neurodegenerative disorders (Mufson et al., 2003). Similar to
subjects with psychostic disorders, functional MRI showed attenuation
of activation in the DLPFC after administration of anti-muscarinic
agents to healthy volunteers (Grasby et al., 1995). Preclinical data
identified that these effects were most likely driven by the muscarinic
M1 receptor subtype rather than the other muscarinic receptor subtypes
(M2-5). The M1 receptor subtypes has high expression rates in fronto-
limbic brain regions which are critically involved in associative
learning and memory (Anagnostaras et al., 2003; Carruthers et al.,
2015; Levey et al., 1991).
The potential loss of M1 receptor functioning in psychotic disorders
was first supported by human post-mortem studies showing sig-
nificantly reduced M1 receptor expression in the DLPFC of schizo-
phrenia patients compared to controls (Dean et al., 2002; Scarr et al.,
2013). Empirical in-vivo evidence, however, for lower M1 receptor
functioning in psychotic disorders is more limited. Experimental drug
xanomeline, which is a M1/4 preferring receptor agonist, has been
shown to improve learning and memory scores in schizophrenia pa-
tients, and in keeping with these results, we showed lower M1 receptor
binding in-vivo in the DLPFC was associated with worse verbal learning
and memory scores in psychotic disorders (Bakker et al., 2018; Shekhar
et al., 2008a). However, it is still unclear whether loss of M1 related
modulation of DLPFC and hippocampus activation during associative
learning and memory drives deficits in psychotic disorders, as xano-
meline’s effects on cognition may be related to the drug’s affinity for
both M1 and M4 receptors, which are also highly expressed in the
hippocampus and striatum. Recent preclinical data highlights the im-
portance of the balance between M1 and M4 signaling for learning and
memory, suggesting that it may in fact be the disruption of this balance
driving deficits seen in psychotic disorders (Gould et al., 2018; Thorn
et al., 2017).
Taken together it is still unknown what role M1 receptor mediated
signaling plays in associative learning and memory deficits of psychotic
disorders in-vivo. Although loss of M1 receptor specific modulation on
associative learning and memory is best studied using a selective M1
agonist drug, these drugs are still in early phases of development and
not yet available for research in humans. Selective M1 antagonists,
however, are available and well tolerated, therefore, we choose to in-
vestigate differences in M1 mediated functional reactivity in psychotic
disorders and controls using a challenge with the M1 antagonist bi-
periden. We were also interested in modeling how loss of M1 related
signaling translated to abnormalities in functional activation under-
lying associative learning and memory. Therefore, we examined whe-
ther functional reactivity to biperiden in subjects with psychotic dis-
orders was related to M1 receptor binding in the DLPFC and hippocampi
using single photon emission computed tomography (SPECT). Based on
previous studies on associative learning and memory we anticipate that
subjects with psychotic disorders will show (1) hypo-activation of the
prefrontal cortex and increased parahippocampal gyrus activation
during associative learning and memory compared to controls, and that
(2) biperiden will attenuate this task-induced activation in the DLPFC in
both groups, with subjects with psychotic disorders showing smaller
reduction in activation under biperiden. Biperiden will also lead to task
induced increased parahippocampal gyrus activation which will be
greater in controls than the subjects with psychotic disorders. Lastly, we
anticipate that (3) subjects with psychotic disorders with lower DLPFC
and hippocampal M1 receptor binding will show greater hypo-activa-
tion in the prefrontal cortex and increased activation in para-
hippocampal regions during associative learning and memory.
2. Materials and methods
2.1. Participants
The current study included 26 subjects with a psychotic disorder
and 29 healthy control subjects matched for age, gender, and IQ. All
subjects with a psychotic disorder were medication-free and were re-
cruited from early detection and intervention programs, the national
first episodic psychosis network, and through advertisements in news-
papers. The 26 subjects diagnosed with a psychotic disorder also par-
ticipated in another study (Bakker et al., 2018). In the previous study,
30 psychotic disorders subjects were included, but only 26 of them were
willing to also participate in the current fMRI study. Diagnosis of a
DSM-IV psychotic disorder was confirmed using the Comprehensive
Assessment of Symptoms and History (CASH) semi-structured interview
(Andreasen et al., 2000). For an overview of the psychotic disorders
included in the study see table 1 of sample demographic variables.
Duration of untreated psychosis was not allowed to be longer than
1 year, and both subjects with psychotic disorders and control subjects
needed to be 18 years of age or older. Exclusion criteria were contra-
indications for MRI, severe neurological or endocrine disorders, current
use of recreational drugs and pregnancy, which were checked through
urine samples. Due to the administration of biperiden subjects with
tardive dyskinesia and narrow angle glaucoma were excluded. Psy-
chotic symptom severity at time of scanning was determined using the
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987).
Ethical approval was obtained from the Amsterdam University Medical
Centres Medical Ethical Committee. Written informed consent was
obtained from all participants after complete description of the study.
2.2. Procedures
All subjects underwent 2 functional MRI sessions on separate days,
one after the oral administration of a placebo and one after the oral
administration of 4 mg of biperiden, in a counterbalanced and rando-
mized controlled trial. Biperiden is a well-tolerated muscarinic receptor
antagonist with a 10-fold higher binding affinity for the M1 receptor
subtype over the other muscarinic receptor subtypes (Kimura et al.,
1999). Scans were conducted 90 min after biperiden administration at
which peak plasma levels of biperiden have been reached (Grimaldi
et al., 1986). Biperiden (Akineton) instant release tablets were used
(Knoll AG, Ludwigshafen, Germany). Only subjects that were diagnosed
Table1
Demographic variables.
Psychotic Disorder Controls stat p
N 26 29
Gender (male/female) 19/7 (20/9) 0.12 0.7
Age in years (M/SD) 27.7 (4.9) 25.6 (5.2) −1.51 0.14
IQ (M/SD) 102 (16) 109 (16) 1.78 0.081
Psychotic disorder subtype
Schizophrenia 11
Schizophreniform disorder 2
Schizoaffective disorder 2
Psychosis NOS 11
Number of episodes: 1/2/3 18/6/2
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with a psychotic disorders received an additional single photon emis-
sion computed tomography (SPECT) scan to quantify M1 receptor
binding using the M1 preferring radiotracer 123I-iododexetimide (123I-
IDEX) (Bakker et al., 2015). These subjects received two 100 mg iodide
tablets the night before and one tablet in the morning of the day of
scanning to prevent thyroid uptake of free radioactive iodide. Each
subject received a bolus injection of approximately 185 MBq (5 mCi) 6h
prior to SPECT scanning. Further details of radiosynthesis and binding
characteristics of 123I-IDEX are extensively described elsewhere (Bakker
et al., 2015; Lavalaye et al., 2001).
2.3. fMRI task paradigm
In order to assess the modulatory role M1 mediated signaling on
functional response during associative learning and memory we
adapted the paired associate learning task (PAL) of the Cambridge
Neuropsychological Test Automated Battery (CANTAB) for MRI (De
Rover et al., 2011). Similar to the PAL CANTAB version of the task,
subjects were presented with a black screen displaying white boxes.
Each box opened randomly for 3 s, with four or more containing a
pattern. After all boxes had opened and closed, a figure would appear in
the center and the subject had to identify the original box it was shown
in (learning phase). The same trial would be repeated showing the same
figures in the same boxes again after which subjects were asked to
identify the box the figure had appeared in (memory phase). Cognitive
load was increased as the task progressed with subjects having to learn
4, 6, and 8 figure-place associations. Figure-place associations were
presented randomly to control for practice effects between sessions. No
figure was be presented twice within the same session. Subjects selected
a box by navigating a red square around a box to the correct location
using the right index finger and middle finger, and the left index finger
was used to confirm the location. The experimental design was an
event-related design with a learning and memory phase followed by a
control phase in which subjects had to select the box to which the arrow
was pointing. The task was programmed using E-prime software. For an
overview of the task see Fig. 1.
2.4. Image acquisition and parameters
All functional magnetic resonance (fMRI) images were acquired
using a Philips Ingenia 3.0 Tesla system (Phillips, Best, The
Netherlands) using gradient echo echo-planar imaging (EPI) with a 32-
channel head sense coil. 37 slices were scanned with 3-mm isotropic
voxel size with a repetition time of 2s, and an echo time of 27 ms.
Additionally, a structural T1 weighted anatomical MPRAGE scan was
made (180 slices, voxel size 1 × 1 × 1 mm, TR: 7.0 ms, TE: 3.2 ms) for
co-registration of functional images, and SPECT images in the psychotic
disorders group. 123I-IDEX SPECT images were obtained using a brain-
dedicated camera (inSPira HD, Neurologica, Boston, USA) (Stam et al.,
2018). Acquisition, attenuation correction, and reconstruction of the
SPECT images was performed as described in Bakker et al., 2018.
2.5. Data analyses
Statistical analysis of group demographic variables was conducted
using IBM SPSS release 24 (SPSS Inc. Chicago IL, USA). Normality of
distribution was tested for all dependent variables using Kolmogorov-
Smirnov and Shapiro-Wilk test. Group differences in gender were as-
sessed using a chi-square test. Group differences in age and IQ were
assessed with an independent samples t-test, and changes in psychotic
symptom severity between placebo and biperiden conditions were as-
sessed using a paired samples t-test. Behavioral responses on the PAL
task were extracted using E-prime and analyzed using IBM SPSS version
24. A 2 factor (group and medication) by 2 level (group: psychotic
disorders/controls and medication: placebo/biperiden) ANCOVA was
used to assess main effect of group, medication, and group by medi-
cation interactions on performance accuracy for 4, 6, and 8 figure place
associations controlling for counterbalance order. Group differences
between accuracy for 4, 6, and 8 figure place associations were assessed
using a paired samples t-test.
All preprocessing and statistical analysis of functional images were
done using FEAT (fMRI expert analysis tool) implemented in FSL 6.0.0
(FMRIB’s software library). All functional images were skull stripped,
realigned, corrected for slice timing, spatially normalized, resampled to
the Montreal Neurological Institute (MNI) 2 mm template, and
smoothed using a 5 mm full width at half maximum Gaussian kernel.
First level contrast images were created by modelling signal changes
during learning and memory phases in comparison to the control con-
dition (see Fig. 1), convolved with a canonical hemodynamic response
function. Six standard rigid body motion parameters were estimated
Fig. 1. Overview of the paired associate learning task (PAL) task as performed during scanning. The initial phase of the task was the learning phase. Each white box
opened for 3s displaying a figure and subjects had to try to remember the figure and it's location. After all boxes have opened and closed each figure appeared in the
center of the screen and subjects had to select the box in which it originally appeared. The same figure place associations were presented twice. During the control
phase subjects had to select the box to which the arrow was pointing.
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and a confound matrix of volumes corrupted by motion effects greater
than two standard deviations was added to the model. A multi-level
(hierarchical) statistical analysis was done to identify group differences
and effects of medication, and group by medication interaction effects.
The group by medication interaction effect was the main analysis of
interest. First, the mean response over the three sessions of increasing
learning and memory load (4, 6, and 8 figure–place associations) were
pooled using a fixed effects analysis using FILM modeling tool (FMRIB’s
Improved Linear Model). Resulting contrast parameter estimates were
assessed in a higher level 2-way mixed effects ANOVA using FLAME
1 + 2 (FMRIB’s Local Analysis Local Analysis of Mixed Effect) to assess
the main effect of medication (placebo/biperiden) and group (psy-
chosis/controls) by medication interaction effect. To test the main ef-
fect of group and group differences a separate higher-level model was
run. For this analysis within-subject mean effect of medication was
pooled in a fixed effects analysis and resulting contrast parameter es-
timates were analysed using a 2 group mean comparison controlling for
IQ and accuracy. Activity was considered significant if Z > 3.1 with a
whole brain corrected cluster probability of p< 0.05.
Lastly, analysis of the SPECT images was done as earlier described
(Bakker et al., 2018), and these data were used to examine how func-
tional response was related to within subject in-vivo M1 receptor
binding in psychotic disorders. M1 receptor binding was quantified in
terms of the binding potential (BPND) which is a tissue ratio of specific
to non-specific binding. Specific binding was measured as 123I-IDEX
binding in the M1-rich hippocampus and DLPFC, and non-specific
binding was measured in cerebellar gray matter which is devoid of M1
receptors. These regions were delineated on subject’s own T1 weighted
image using Freesurfer (Fischl et al., 2002), as earlier described (Bakker
et al., 2018). Relationship between M1 receptor binding and functional
reactivity to biperiden during learning and memory was assessed using
a fixed effects analysis with M1 binding added as covariate regressor,
controlling for task performance accuracy.
3. Results
3.1. Demographic variables
Subjects did not differ significantly in age, gender, or IQ. The sub-
jects with psychotic disorders reported mild psychotic symptoms and no
difference in psychotic symptom severity was found between scanning
sessions. All subjects were antipsychotic medication-free, and 5 subjects
were antipsychotic-naive. Two subjects that were being treated with a
subtherapeutic dose of a non-cholinergic antipsychotic (haloperidol,
1 mg; quetiapine, 200 mg) underwent a washout (5 times the mean
terminal elimination half-life of the specific antipsychotic) prior to in-
clusion. Sample details and statistics are summarized in Tables 1 and 2.
3.2. Cognitive performance
Estimated IQ was trend significantly (p = 0.081) lower in the
subjects diagnosed with a psychotic disorder than the control group.
Therefore, it was included as covariate in all further analyses.
Correcting for IQ and counterbalance results showed a significant main
effect for group on the amount of accurate responses on the PAL during
the memory phase (F = 3.08 (1,26), p = 0.027), but not the learning
phase. Patients were significantly worse at recalling 4, 6, and 8 figure-
place associations than controls in the memory phase. There was also a
significant main effect for medication (placebo vs biperiden condition)
on accuracy of recall of 4, 6, and 8 figure-place associations in the
memory phase, showing significantly lower accuracy scores after bi-
periden compared to the placebo condition in both groups (F = 4.7
(25,26), p = 0.035). No main effect of medication was found on ac-
curacy in the learning phase. No significant group by medication in-
teraction effect was found in either the learning or the memory phase.
Post hoc paired samples t-test examining the effect of biperiden on
accuracy for each cognitive load showed biperiden significantly im-
paired learning and memory at all cognitive loads except for the highest
cognitive load of 8 figure-place associations, and the 6 and 8 figure-
place associations in subjects with psychotic disorders. This may be due
to a ceiling effect. Group means and standard deviations of repeated
measures analyses are displayed in table 3.
3.3. Functional reactivity
3.3.1. Psychosis vs controls
3.3.1.1. Learning phase. During the learning phase no significant main
effect of group was found in functional activation between control
subjects and subjects with a psychotic disorder. A significant main
effect of medication (both groups showing a significant increased
activation under biperiden) was found in the right superior temporal
gyrus (p < 0.001; x: 64 y: −4 z: −2; Zmax: 9.28), left parahippocampal
gyrus (p < 0.001; x: −30 y: −16 z: −28; Zmax: 7.58) and left
precuneus (p = 0.03; x: 2 y: −66 z:60; Zmax: 5.67). These clusters were
also identified as showing a significant group by medication interaction
effect (main comparison of interest), showing both controls and the
subjects with a psychotic disorder having increased functional
activation in these areas under biperiden, but in the subjects with a
psychotic disorder this was significantly greater than in controls. See
Fig. 2A. Comparisons were corrected for accuracy, IQ, and multiple
comparisons.
3.3.1.2. Memory phase. A significant main effect for group was found in
the left middle frontal gyrus (p < 0.001; x: −38 y: 18 z: 52;
Zmax:10.5), left lateral occipital lobe (p < 0.001; x: −36 y: −74
z:44; Zmax:8.06), and fusiform cortex (p = 0.025; x:40 y: −16 z: −26;
Zmax:5.99). Control subjects showed significantly greater activation in
these clusters than the subjects diagnosed with a psychotic disorder. No
significant main effect for medication was found. Results did show a
significant group by medication interaction effect on functional
activation in the right superior temporal gyrus (p = 0.01; x: −64 y:
−4 z: −2; Zmax: 9.36) and left parahippocampal gyrus (p < 0.001; x:
−30 y: −16 z: −28; Zmax: 4.27). The subjects diagnosed with a
psychotic disorder showed significant hyperactivation in these regions
under biperiden, whereas control subjects showed attenuation of
functional response (see Fig. 2B). All comparisons were corrected for
IQ, accuracy of performance, and multiple comparisons.
3.4. Relationship between functional response to biperiden and M1 receptor
binding
In the placebo condition a significant positive correlation was found
between hippocampal M1 binding and functional activation in the left
middle temporal gyrus (p = 0.036, x: −50 y: −6 z: −20; Zmax: 5.75) in
the subjects diagnosed with a psychotic disorder. Lower hippocampal
M1 binding also significantly predicted a reduced functional response to
biperiden during learning (smaller attenuation of activation under bi-
periden compared to high binders) in the left inferior temporal gyrus
(p = 0.013; x: −44 y: −2 z: −30; Zmax:6.58) with significant local
Table 2
Clinical variables.
Clinical variables Placebo Biperiden statistic p
Psychotic disorders
positive symptom severity 9.02 (3.2) 9.13 (4.1) −0.29 0.77
negative symptom severity 9.41 (3.8) 9.39 (4.0) 0.05 0.91
general psychopathology 19.81 (5.9) 19.39 (5.4) 0.87 0.39
Controls
positive symptom severity 7.2 (0.8) 7.1 (0.4) 1.01 0.33
negative symptom severity 7.45 (0.3) 7.1 (0.06) 1.05 0.31
general psychopathology 16.9 (0.37) 16.5 (0.31) 0.77 0.45
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peak activation within this cluster in the left fusiform gyrus (x: −40 y:
−12 z: −22; Zmax: 6.32) and left parahippocampal gyrus (x: −30 y:
−8 z: −24; Zmax: 5.82). In contrast, lower M1 binding in the DLPFC
significantly predicted lower functional reactivity to biperiden (smaller
attenuation of activation under biperiden) during the memory phase in
the left cingulate gyrus (p < 0.001; x: −2 y:34 z: −6; Zmax:7.57) and
right cingulate gyrus although this finding in the right hemisphere did
not survive multiple comparison’s correction. See Fig. 3.
3.5. Relationship between functional response to biperiden and psychotic
symptom severity
Greater negative symptom severity was associated with significantly
lower functional reactivity to biperiden in the right caudate nucleus
(p = 0.023; x: 14 y:20 z: −2; Zmax:4.2) during learning, and in the left
parahippocampal gyrus (p = 0.043; x: −32 y: 0 z: −24; Zmax: 4.73)
during the memory phase. Other psychotic symptoms did not show a
significant association with functional reactivity to biperiden.
4. Discussion
The current study assessed the modulatory role of the muscarinic M1
receptor on associative learning and memory in medication-free sub-
jects with a psychotic disorder and matched controls. In contrast to the
first hypothesis, no evidence for task induced DLPFC hypoactivation
was found in the subjects with a psychotic disorder compared to con-
trols during the learning phase of the task. Biperiden also did not cause
DLPFC hypoactivation in controls or further decreased DLPFC hy-
poactivation in the subjects with psychotic disorders. In similar vein, no
evidence for increased parahippocampal gyrus activation was found in
the subjects with psychotic disorders compared to controls during
learning, but biperiden did induce significantly increased activation in
Table 3
Accuracy of responses on the PAL task.
Accuracy N (fig) Psychotic disorder Controls
Placebo (mean/SD) Biperiden (mean/SD) P Placebo (mean/SD) Biperiden (mean/SD) p
Phase 1: Learning 4 3.07 (0.2) 2.98 (0.3) < 0.001 3.24 (0.2) 3.11 (0.3) <0.001
6 3.28 (0.01) 3.09 (0.02) <0.001 3.29 (0.02) 3.08(0.01) <0.001
8 4.40 (0.3) 3.98 (0.05) 0.002 4.3(0.05) 3.99 (0.3) <0.001
Phase 2: Memory 4 3.34 (0.5) 2.88 (0.6) < 0.004 4.52 (0.1) 3.28 (0.2) <0.001
6 3.35 (0.2) 3.33 (0.2) 0.9 ns 5.34 (1.1) 3.06 (0.09) <0.001
8 3.85 (0.9) 3.76 (0.3) 0.7 ns 4.65 (0.6) 4.34 (0.9) 0.2 ns
All findings were corrected for IQ and counterbalance.
Fig. 2. A. Overview of clusters showing a significant group by drug interaction during the learning phase, with both groups showing significantly increased functional
activation in the right superior temporal gyrus, left parahippocampal gyrus, and left precuneus under biperiden compared to placebo. In the subjects diagnosed with a
psychotic disorder this hyperactivation was significantly greater compared to controls. B. Overview of clusters showing a significant group by drug interaction effect
during the memory phase. Patients diagnosed with a psychotic disorder had significantly increased activation in these clusters whereas controls showed attenuation
of activation. All findings were corrected for IQ, accuracy and multiple comparisons. R: right; L: left.
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both subjects with psychotic disorders and controls of the para-
hippocampal gyrus, and this increase was significantly greater in the
subjects with psychotic disorders.
In line with our hypothesis results did support significant hy-
poactivation of the DLPFC (left middle frontal gyrus) in the subjects
with a psychotic disorder compared to controls during memory, but no
evidence for increased parahippocampal gyrus activation was found.
Under biperiden however, supporting the hypothesis, significant hy-
peractivation was found in the subjects with a psychotic disorder con-
trols however, showed significant hypoactivation.
Lastly, no evidence was found for lower M1 binding and patterns of
greater DLPFC hypoactivation and increased parahippocampal cortex
activation in the subjects with psychotic disorders during learning or
memory. Instead lower hippocampal M1 binding predicted lower
Fig. 3. A: A1&A2: Lower hippocampal M1 binding significantly predicted a smaller functional response to biperiden in left inferior temporal gyrus, fusiform gyrus,
and parahippcampal gyrus during learning suggesting less M1 reserve to elicit functional response during learning in the subjects with psychotic disorder. A3:
Activation in significant clusters associated with hippocampal M1 binding in the subjects with a psychotic disorder plotted out for both groups. B: B1&B2: Lower M1
binding in the DLPFC significantly predicted a decreased functional response in the left cingulate gyrus in to biperiden during the memory phase. Lower DLPFC M1
binding as associated with lower ability to functionally activate this area after biperiden. B3: Activation in significant clusters associated with DLPFC M1 binding in
the subjects diagnosed with a psychotic disorder plotted out for both groups. k: cluster size, pla: placebo bip: biperiden.
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functional response of the fusiform gyrus and parahippocampal gyrus to
biperiden during learning, and lower M1 binding in the DLPFC pre-
dicted lower functional response in the cingulate gyrus during memory.
4.1. Functional activation differences between the subjects with psychotic
disorders and controls
In the current study we did not replicate findings of earlier studies
in schizophrenia showing significant hypoactivation in the DLPFC and
increased parahippocampal gyrus activation during associative
learning, but only showed DLPFC (middle frontal gyrus) hypoactivation
in the memory phase (Ragland et al., 2012, 2009, 2004). Previous
studies concluded that in general the memory phase seemed to be more
affected than the learning phase which is supported by our results
(Barch and Sheffield, 2014). Lack of DLPFC hypoactivation during the
learning phase in our cohort may be attributed to the fact that they
were less ill. In the current study subjects were experiencing mild
symptoms and were not as cognitively impaired as those investigated in
previous studies, which may account for differences in results. In this
regard, it is of interest that another previous study also did not find
DLPFC hypoactivation in subjects with psychosis that were only mildly
impaired (Ragland et al., 2012). Similarly, previous findings may have
been confounded by use of antipsychotic medication that can affect
cognitive functioning (MacKenzie et al., 2018).
4.2. Group difference in functional sensitivity to biperiden
Contrary to anticipated, biperiden did not attenuate task-induced
activation in the DLPFC during associative learning, in neither control
subjects, nor those diagnosed with a psychotic disorder, but instead
elicited a significantly increased functional response in the para-
hippocampal gyrus in both groups, with patients having even greater
hyperactivation. In the subjects with an psychotic disorder the greater
hyperactive response was more widespread and included the superior
temporal gyrus. These results suggest that loss of M1 signalling by bi-
periden may have a greater impact on functional response in temporal
limbic structures rather than the DLPFC. Associative learning depends
on glutamate driven longterm potentiation (LTP) in the hippocampus of
signals from the environment (Takeuchi et al., 2014). M1 and M4 cri-
tically modulate the underlying glutamatergic signalling of LTP in the
hippocampus. Preclinical data has shown that loss of M1 mediated
signalling leads to loss of the controlled suppression of glutamate un-
derlying LTP leading to a hyperactive response. The significantly
greater activation under biperiden in learning and memory in the
psychosis patients could be driven by a greater loss in M1 mediated
suppression on glutamate in the hippocampus compared to controls,
potentially due to lower reserve of M1 receptors. Despite the subjects
with psychotic disorders having very mild impairments in associative
learning and memory they seem to be functionally more sensitive to M1
antagonism than controls.
These preliminary data suggest that greater functional sensitivity of
limbic structures in psychotic disorders in learning and memory may
have it’s origin in loss of muscarinic M1 mediated signalling. These
findings are important, as the preclinical rodent (prenatal) methyla-
zoxymethanol acetate (MAM) model of schizophrenia has also shown
hippocampal hyperactivity from direct cell recordings (Lodge, 2013). In
this model the hyperactivity translates to an increased drive on ventral
tegmentum firing which results in an increased dopamine synthesis and
release in the striatum (Lodge and Grace, 2011). As such, targeting the
M1 mediated signalling upstream may be beneficial to suppressing
striatal hyperdopaminergia, in addition to improving cognition. Al-
though more conclusive studies would need to be done, our data sug-
gests that the parahippocampal gyrus hyperactivation reported in pre-
vious studies may not be a compensatory strategy as suggested but be
disease mechanistic. It may also ultimately explain why hippocampal
and limbic structure atrophy is seen in chronic schizophrenia
(Lieberman et al., 2018).
4.3. Relationship between functional sensitivity to biperiden and M1
receptor binding
In this study we also assessed whether differences in functional re-
activity to biperiden in the subjects diagnosed with a psychotic disorder
showed any direct relationship with M1 receptor binding (Fig. 3). Re-
sults showed that levels of hippocampal M1 binding specifically drove
functional sensitivity to biperiden in limbic areas during the learning
phase, with no association found for M1 binding in the DLPFC. These
results add to our previous findings showing an association between
lower hippocampal M1 binding and greater impairments in verbal
learning and memory task (Bakker et al., 2018). Current results suggest
this may be explained by a lower M1 mediated functional response in
limbic areas in the low binding subjects.
In contrast, M1 binding in the DLPFC seemed to play more of a role
during the memory or recall phase. It was specifically associated with
greater functional sensitivity to biperiden in the bilateral cingulate
gyrus (Fig. 3). The cingulate gyrus receives processed information from
the hippocampus and parahippocampal gyrus to store in the cortex
allowing for memory retrieval (Brem et al., 2013). Thus, lowered M1
mediated signalling in the DLPFC seems to translate to lower activation
of regions involved in the retrieval of traces formed in the learning
phase. It is still unclear whether this is secondary to functional changes
underlying learning processes or exist independently. Patients diag-
nosed with a psychotic disorder with lower M1 binding in the DLPFC
which has been hypothesised to be present in a subgroup of patients
(Dean et al., 2002) may show greater impairments in memory retrieval
capacity. More generally, current data show relatively greater degree of
abnormalities in functional response to learning compared to memory
under biperiden, suggesting psychotic disorders may be more char-
acterised by lim bic changes in muscarinic M1 receptor sensitivity. This
is in line with earlier meta-analytical studies showing greater functional
abnormalities in paired associate encoding (learning) than retrieval in
schizophrenia (Ragland et al., 2012).
4.4. Relationship between functional sensitivity to biperiden and severity of
psychotic symptoms
The present results also showed that some of the abnormalities in
functional response to biperiden were tied to negative symptom se-
verity. Reduced functional response to biperiden in the caudate nucleus
(during learning) and parahippocampal gryus (during memory) was
found in the subjects with greater negative symptoms severity. The
caudate nucleus plays an important role in the association of two sti-
muli and hyperactivation of this area is implicated in abnormal pro-
cessing of environmental cues giving rise to psychotic symptoms
(McCutcheon et al., 2019). The caudate nucleus is an integral part of
the fronto-striatal limbic circuitry, and although the genesis of the ne-
gative symptoms has been tied loosely to alterations in dopamine,
noradrenaline and glutamate in this circuitry, the exact underlying
pathology is not understood (Mitra et al., 2016). Current results seem to
suggest that altered, or lower M1 functioning may also play a role in
negative symptom severity and linked to fronto-striatal-limbic func-
tioning. This may underlie the efficacy of antipsychotic clozapine treat
negative symptoms (Khan and Zaidi, 2017), and the positive effect of
M1/4 agonist xanomeline on negative symptoms in patients with
chronic schizophrenia (Shekhar et al., 2008b). Clozapine’s efficacy to
improve negative symptoms has been attributed to the formation of its
brain penetrant metabolite n-desmethylclozapine that acts a positive
allosteric modulator at the M1 receptor (Sur et al., 2003).
Taken together results from this study point to differences in func-
tional sensitivity of the muscarinic system during learning and memory
in patients diagnosed with a psychotic disorder compared to controls.
This difference is particularly apparent in temporal- limbic areas and
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seemingly already present in early phases of the disorder and in mildly
impaired subjects. This increased muscarinic sensitivity in limbic-tem-
poral areas in the subjects with psychotic disorders was related to
hippocampal M1 receptor binding, rather than M1 receptor binding in
the DLPFC.
5. Strengths and limitations
A key strength of the current study was that the subjects diagnosed
with a psychotic disorder were medication free, and results did not have
confounding effects of medication, or affected by indirect interaction
effects between biperiden and antipsychotic medication affecting do-
paminergic and serotonergic signalling. As cognitive symptoms often
develop prior to the onset of psychotic disorder, alteration in M1 sig-
naling has been proposed to be an upstream factor in the dysregulation
of dopamine and serotonergic systems making it paramount to in-
vestigate medication free subjects (Vakalopoulos, 2014).
Another major strength was that differences in functional sensitivity
to biperiden between controls and subjects with psychotic disorders
was linked to regional M1 receptor binding in the subjects with psy-
chotic disorders. These findings are critical to ongoing efforts to de-
velop M1 agonists to improve cognition (Erskine et al., 2019; Melancon
et al., 2013). Also both biperiden and 123I-IDEX have been shown to
preferentially bind to the M1 receptor (Bakker et al., 2015; Klinkenberg
and Blokland, 2011). Previous studies have used non-selective M1/4
tracer IQNB or used scopolamine, an antagonist at the all muscarinic
receptor subtypes, to investigate the role of the muscarinic system in
schizophrenia or cognition which made it more difficult to attribute
finding specifically to the M1 receptor. Notwithstanding this, we cannot
rule out marginal effects on the functional response by biperiden
blockade of the M4 receptor that has high density in the hippocampus.
In addition, because both biperiden and 123I-IDEX are antagonists, they
sample all M1 receptors rather than only those in a high-affinity state.
The modulatory effects of the M1 receptor on the functional response
will be mediated by those in a high affinity state, which we did not
directly assess in this study.
Unfortunately, we were not allowed to acquire in-vivo M1 receptor
data in the control subjects by the medical ethical board. Therefore, it
was not possible to determine whether the lower hippocampal M1
binding that was shown to predict loss of functional activation in
striatal-limbic regions during associative learning and memory was
significantly reduced compared to controls. In addition, the subjects
with a psychotic disorder included in this study displayed mild to
moderate symptoms, as such findings may not translate well to more
severely affected patients.
6. Conclusion
The current study showed an abnormally high hyperactivation of
the parahippocampal gyrus during associative learning and memory in
subjects diagnosed with a psychotic disorders in response to biperiden
which may be related to loss of M1 mediated modulation over gluta-
mate in these regions. Results further linked this hyperactivation to
lower hippocampal M1 receptor binding, rather than M1 binding in the
DLPFC. Lastly, subjects with psychotic disorder with greater negative
symptom severity and lower hippocampal and DLPFC M1 binding
showed greater loss of functional activation in the striatal-limbic cir-
cuitry. Performance on the PAL task together with negative symptom
profile may be sensitive marker for greater therapeutic sensitivity to
drugs targeting the muscarinic system.
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